Highlights and Quick Summary
- Average Payables for the quarter ending March 31, 2022 was $2.98 Million (a 73.23% increase compared to previous quarter)
- Year-over-year quarterly Average Payables increased by 92.79%
- Annual Average Payables for 2021 was $1.72 Million (a -36.97% decrease from previous year)
- Annual Average Payables for 2020 was $2.73 Million (a 5.24% increase from previous year)
- Annual Average Payables for 2019 was $2.59 Million (a 34.28% increase from previous year)
Visit stockrow.com/ALNA
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Average Payables of Allena Pharmaceuticals, Inc.
Most recent Average Payablesof ALNA including historical data for past 10 years.Interactive Chart of Average Payables of Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc. Average Payables for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | $2.98 | – | – | – | – |
| 2021 | $1.72 | $2.12 | $1.55 | $2.31 | $1.72 |
| 2020 | $2.73 | $2.41 | $1.43 | $2.17 | $2.73 |
| 2019 | $2.59 | $2.69 | $1.59 | $2.38 | $2.59 |
| 2018 | $1.93 | $1.85 | $1.42 | $2.38 | $1.93 |
| 2017 | – | – | $1.93 | $1.85 | $1.59 |
| 2016 | – | – | – | – | $1.71 |
| 2015 | $1.42 | – | – | – | $1.71 |
Business Profile of Allena Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.